Ned Davis Research downgraded shares of Myriad Genetics (NASDAQ:MYGN) from a buy rating to a neutral rating in a research note released on Monday morning, Stock Ratings Network.com reports.
Shares of Myriad Genetics (NASDAQ:MYGN) opened at 25.31 on Monday. Myriad Genetics has a 52 week low of $22.61 and a 52 week high of $38.27. The stock’s 50-day moving average is $26.71 and its 200-day moving average is $28.44. The company has a market cap of $2.036 billion and a P/E ratio of 14.30. Myriad Genetics also was the recipient of some unusual options trading on Monday. Stock traders bought 11,342 put options on the stock. This represents an increase of approximately 365% compared to the average daily volume of 2,438 put options.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 13th. The company reported $0.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.09. The company had revenue of $174.10 million for the quarter, compared to the consensus estimate of $159.87 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 30.9% on a year-over-year basis. Analysts expect that Myriad Genetics will post $1.91 EPS for the current fiscal year.
MYGN has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a neutral rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Thursday, September 19th. They now have a $27.00 price target on the stock. Finally, analysts at Cowen and Company downgraded shares of Myriad Genetics (NASDAQ:MYGN) from an outperform rating to a market perform rating in a research note to investors on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company’s stock. Myriad Genetics has an average rating of Hold and an average price target of $34.00.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.